Metabolomics study reveals increased deoxycholic acid contributes to deoxynivalenol-mediated intestinal barrier injury

Life Sci. 2024 Jan 1:336:122302. doi: 10.1016/j.lfs.2023.122302. Epub 2023 Nov 26.

Abstract

Aims: Deoxynivalenol (DON), namely vomitoxin, is one of the most prevalent fungal toxins in cereal crops worldwide. However, the underlying toxic mechanisms of DON remain largely unknown.

Main methods: DON exposure-caused changes in the murine plasma metabolome and gut microbiome were investigated by an LC-MS/MS-based nontargeted metabolomics approach and sequencing of 16S rRNA in fecal samples, respectively. Cellular models were then used to validate the findings from the metabolomics study.

Key findings: DON exposure increased intestinal barrier permeability evidenced by its-mediated decrease in colonic Claudin 5 and E-cadherin, as well as increases in colonic Ifn-γ, Cxcl9, Cxcl10, and Cxcr3. Furthermore, DON exposure resulted in a significant increase in murine plasma levels of deoxycholic acid (DCA). Also, DON exposure led to gut microbiota dysbiosis, which was associated with DON exposure-caused increase in plasma DCA. In addition, we found not only DON but also DCA dose-dependently caused a significant increase in the levels of IFN-γ, CXCL9, CXCL10, and/or CXCR3, as well as a significant decrease in the expression levels of Claudin 5 and/or E-cadherin in the human colonic epithelial cells (NCM460).

Significance: DON-mediated increase in DCA contributes to DON-caused intestinal injury. DCA may be a potential therapeutic target for DON enterotoxicity.

Keywords: Bile acids; Chemokines; Deoxycholic acid; Deoxynivalenol; Intestinal barrier; Metabolomics.

MeSH terms

  • Animals
  • Cadherins
  • Chromatography, Liquid
  • Claudin-5
  • Deoxycholic Acid / toxicity
  • Humans
  • Intestinal Diseases*
  • Mice
  • RNA, Ribosomal, 16S
  • Tandem Mass Spectrometry*

Substances

  • deoxynivalenol
  • RNA, Ribosomal, 16S
  • Claudin-5
  • Cadherins
  • Deoxycholic Acid